Clinical Trial: A multicenter prospective observational study evaluating the efficacy and safety of amivantamab plus lazertinib in patients with EGFR (exon19 deletion or L858R)-mutated advanced or recurrent NSCLC previously treated with osimertinib (with or without chemotherapy) (Japan)

Tokyo, July 29 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000062375) titled 'A prospective observational study of amivantamab plus lazertinib in patients with EGFR-mutated non-small cell lung cancer previously treated with osimertinib (NJLCG2501)' on July 28.

Study Type: Observational

Primary Sponsor: Institute - Tohoku University

Condition: Condition - EGFR-mutated advanced or recurrent non-small cell lung cancer Classification by malignancy - Malignancy Genomic information - NO

Objective: Narrative objectives1 - To prospectively evaluate the efficacy and safety of amivantamab plus lazertinib in patients with EGFR-mutated advanced or recurrent non-small cell lung cancer previously treate...